USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MICROSURFACES INC
Address:
3913 Todd Lane
SUITE 102
Austin, TX 78744-
Phone:
(612) 789-0104
URL:
N/A
EIN:
411974237
DUNS:
166478318
Number of Employees:
5
Woman-Owned?:
Yes
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $400,000.00 4
SBIR Phase II $1,980,424.00 3

Award List:

ORIENTED PROTEIN MICROARRAY FOR FUNCTIONAL STUDIES

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant):A novel method is proposed for the fabrication of protein microarrays using metal coordination chemistry and poly-histidine tagged protein molecules. The proposed method is aimed at microarrays with highly selective and facile linking chemistry, with uniform and… More

SBIR Phase II: Membrane Protein Microarrays

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project proposes to develop a product platform based on polymer cushion coated glass slides with controlled surface charge density for membrane protein microarray fabrication. The key technical objectives for Phase II research are : (a) to… More

Oriented Protein Microarray for Functional Studies

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$733,438.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The proposed research is aimed at developing protein microarrays as a superior technology oriented and viable product for the proteomics market. During Phase-I research, the PI and coworkers have successfully demonstrated the feasibility of fabricating protein… More

SBIR Phase II: Membrane Protein Microarrays

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research (SBIR) Phase II project proposes to develop a product platform based on polymer cushion coated glass slides with controlled surface charge density for membrane protein microarray fabrication. The key technical objectives for Phase II research are : (a) to… More

SBIR Phase I: High Throughput Screening of Multivalent Drugs and Nanomedicine

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
NSF
Principal Investigator:
Abstract:
This Small Business Innovation Research Phase I project develops cell membrane mimetic-microarrays for high-throughput screening and analysis of multivalent drug candidates, particularly nanomedicine. Traditional drugs based on mono-valent and high-affinity interactions can lead to non-specific side… More

Cell Mimic Microarrays for Multivalent Pathogen Characterization and Detection

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This research project aims to develop cell mimic microarrays for the profiling, characterization, and detection of pathogens. The proposed approach exploits a common mechanism at the initial stage of pathogen attack, na mely the recognition of and attachment onto… More

Cell Mimic Microarrays for the Multivalent Pathogen Profiling and Characterization

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$746,986.00
Agency:
HHS
Principal Investigator:
Athena Guo – 512-916-0802
Abstract:
DESCRIPTION (provided by applicant): This research project aims to develop fluidic glycan microarrays for the quantitative profiling and characterization of pathogens, and for the screening of pathogen inhibitors and the development of vaccines. The approach targets a common mechanism at the… More